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The Postural Tachycardia Syndrome (POTS) is the most common disorder seen in
autonomic clinics. Cardinal hemodynamic feature of this chronic and debilitating disorder
of orthostatic tolerance is an exaggerated orthostatic tachycardia (≥30 bpm increase
in HR with standing) in the absence of orthostatic hypotension. There are multiple
pathophysiological mechanisms that underlie POTS. Some patients with POTS have
evidence of elevated sympathoneural tone. This hyperadrenergic state is likely a driver
of the excessive orthostatic tachycardia. Another common pathophysiological mechanism
in POTS is a hypovolemic state. Many POTS patients with a hypovolemic state have
been found to have a perturbed renin-angiotensin-aldosterone profile. These include
inappropriately low plasma renin activity and aldosterone levels with resultant inadequate
renal sodium retention. Some POTS patients have also been found to have elevated
plasma angiotensin II (Ang-II) levels, with some studies suggesting problems with
decreased angiotensin converting enzyme 2 activity and decreased Ang-II degradation.
An understanding of these pathophysiological mechanisms in POTS may lead to more
rational treatment approaches that derive from these pathophysiological mechanisms.
Keywords: postural tachycardia syndrome, aldosterone, angiotensin II, blood volume, hyperadrenergic activity,
Autonomic Nervous System, neuropathy, orthostatic intolerance
INTRODUCTION
Postural Tachycardia Syndrome (POTS) is a debilitating syn-
drome that is characterized by symptoms of presyncope when
assuming an upright position. This syndrome is the most com-
mon disorder seen in autonomic specialty clinics and affects
500,000–3,000,000 individuals in the United States (Robertson,
1999). Young women are disproportionately affected, with nearly
80–85% of cases occurring in women and most of childbear-
ing age (Garland et al., 2007). The cardinal hemodynamic
feature of this syndrome is an increase in heart rate (HR)
by ≥30 bpm on assuming an upright position within 10min
in the absence of orthostatic hypotension (a drop in systolic
blood pressure (BP) >20mmHg or a drop in diastolic BP
>10mmHg) (Freeman et al., 2011; Raj, 2013). In addition, symp-
toms of orthostatic intolerance (palpitations, light-headedness,
chest discomfort, or dyspnea) must accompany this ortho-
static tachycardia, improve with recumbency and persist for
at least 6 months. Symptoms must also occur in the absence
of conditions that cause orthostatic tachycardia, such as pro-
longed bedrest, use of medications that impair autonomic reg-
ulation (vasodilators, diuretics, antidepressants, or anxiolytic
agents), or chronic debilitating disorders that cause tachycar-
dia (such as dehydration, anemia, or hyperthyroidism) (Raj,
2013).
Neurohormonal dysregulation has been identified in a number
of patients with POTS. We will discuss the data supporting this
implication and review the neurologic and hormonal aspects of
POTS as it pertains to the pathophysiology of this condition.
PATHOPHYSIOLOGY OF POTS (TABLE 1)
POTS is a heterogeneous syndrome with several different patho-
physiological mechanisms that can result in the typical POTS
presentation, and a few more common ones are highlighted
in this manuscript (Figure 1) (Raj, 2013). Neuropathic POTS
is a condition with a partial neuropathy where there is pref-
erential denervation of sympathetic nerves in the lower limbs
that may account for local/regional blood flow abnormalities
including venous pooling (Jacob et al., 2000; Stewart et al.,
2003). A state of hypovolemia also exists in the majority of
POTS patients. This phenomenon of low blood and plasma
volumes in the presence of inappropriately low levels of renin
and aldosterone in POTS patients has been referred to as the
“renin-aldosterone paradox” (Raj et al., 2005a). This hypovolemic
state can lead to decreased venous return, and contributes to
presyncopal symptoms in addition to reflex tachycardia. Though
many POTS patients have elevated plasma norepinephrine sec-
ondary to partial autonomic neuropathy or hypovolemia, central
hyperadrenergic POTS is a variant of POTS where individu-
als have high levels of upright plasma norepinephrine in the
absence of these two findings (Raj et al., 2005a; Mustafa et al.,
2011; Raj, 2013). A few patients in one family have a specific
genetic abnormality linked to a single point mutation in the nore-
pinephrine transporter with subsequent diminished clearance
of norepinephrine (Shannon et al., 2000). This hyperadrener-
gic state is thought to drive the orthostatic tachycardia in these
patients (Figure 1). The different pathophysiological mechanisms
are not mutually exclusive, and POTS patients will often have
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Table 1 | Some pathophysiological mechanisms of POTS and related treatments.
Major pathophysiological Pathophysiology Treatments Mechanism of therapy
mechanisms of POTS
Partial autonomic
neuropathy
Partial autonomic
neuropathy in lower
extremities
Midodrine (Jacob et al., 1997;
Hoeldtke et al., 2006; Lai et al., 2009;
Ross et al., 2014)
An alpha-1 agonist that increases
peripheral vasoconstriction
Abnormal splanchnic
blood flow and pooling
Octreotide (Hoeldtke and Davis, 1991;
Hoeldtke et al., 2006)
A somatostatin analog that decreases
splanchnic blood flow
Perturbed renin-angiotensin
aldosterone system and
hypovolemia
Inappropriately low levels
of renin and/or
aldosterone
Low blood and/or plasma
volume
Exercise (Fu et al., 2011)
Exercise (Fu et al., 2011)
Fludrocortisone (Freitas et al., 2000)
Erythropoietin (Hoeldtke et al., 1995;
Kanjwal et al., 2012)
Precise mechanism unclear, but increases
renin:aldosterone ratio
Increases plasma volume
A mineralocorticoid that increases sodium
and water retention
A hormone that increases blood volume
Saline Infusions (Jacob et al., 1997) Acutely increases plasma volume
DDAVP (Coffin et al., 2012) An ADH analog that increases
intravascular volume
Hyperadrenergic
State
Increased secretion and
clearance of
norepinephrine
Propranolol (Raj et al., 2009; Fu et al.,
2011);
A non-selective beta-blocker that impairs
sympathetic activation
Pyridostigmine (Raj et al., 2005b;
Singer et al., 2006; Kanjwal et al.,
2011)
An acetylcholinesterase inhibitor that
increases parasympathetic activity and
slows heart rate
an overlap of features from a number of these aforementioned
variants.
NEUROPATHIC POTS (PARTIAL AUTONOMIC NEUROPATHY)
In 1988, Streeten et al. first published a report regarding the
pathophysiology of POTS. In 34 patients with symptoms of
orthostatic intolerance, 10 patients exhibited orthostatic increases
in HR >30 bpm. In these 10 individuals, radioisotopic measure-
ments of orthostatic pooling of blood in the calf was significantly
greater compared to healthy subjects (P < 0.01), which was sug-
gestive of at least partial autonomic neuropathy related to a
portion of the autonomic system (Streeten et al., 1988).
Abnormal blood flow abnormalities in the lower extremity
Stewart and Weldon confirmed increases in orthostatic leg vol-
ume and venous blood flow consistent with excessive pooling
in the lower extremities in a pediatric POTS population using
strain-gauge measurements (Stewart and Weldon, 2000). They
further dichotomized POTS patients into two groups based on
lower extremity venous pressure (VP) > 20mmHg (high-VP
POTS) or ≤20mmHg (low-VP POTS) and found defective vaso-
constriction in both groups as evidenced by significantly more
blood flow in the calves during orthostasis compared to healthy
subjects. While supine, high-VP POTS group had normal arte-
rial resistance but lower blood flow in the lower extremities
compared to healthy subjects, and the low-VP POTS group
had less arterial resistance and higher blood flow in the lower
extremities compared to healthy subjects (Stewart and Weldon,
2001). High-VP POTS patients, also referred to as “low-flow”
POTS patients (LFP), had inappropriate vasodilation during
orthostasis instead of the vasoconstriction that was seen in healthy
subjects and “high-flow” POTS (HFP) patients. The excessive
blood pooling in the lower extremities and increased ortho-
static leg volume is due to a defect in arteriolar vasoconstric-
tion and not an abnormality of venous capacitance (Stewart,
2002; Stewart et al., 2003). These studies indicate there is
an abnormal vascular response in the extremities that predis-
poses POTS patients to venous pooling secondary to arteriolar
dysregulation.
Abnormal regional blood volume regulation
Both Doppler ultrasound and segmental impedance plethysmog-
raphy (Diedrich and Biaggioni, 2004) have indicated that there is
abnormal blood flow and pooling in the splanchnic circulation of
many POTS patients (Tani et al., 2000; Stewart and Montgomery,
2004). Both “low-flow” and “high-flow” patients had signifi-
cantly greater decreases greater decreases in thoracic blood flow
versus healthy subjects during orthostasis (P < 0.025 and P <
0.004 respectively). In addition, “low-flow” POTS patients had
increased splanchnic blood flow compared to healthy subjects
(P < 0.01) with upright position (Stewart et al., 2006b). “High-
flow” POTS patients had increased pooling in the pelvis and
legs versus healthy subjects (P < 0.05 and P < 0.025 respectively)
(Stewart and Montgomery, 2004).
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FIGURE 1 | Pathophysiological mechanisms of postural tachycardia syndrome. Cartoon representation of how 3 major neuronal and hormonal
abnormalities and their immediate effects may cause symptoms commonly associated with POTS.
Partial autonomic neuropathy
An explanation for this adverse blood pooling is a partial auto-
nomic neuropathy. Schondorf and Low initially found evidence
of generalized autonomic neuropathy in patients with POTS
(Schondorf and Low, 1993). Later, Jacob et al. showed that
there was a defect in sympathetic nervous system innervations
of the lower extremity in POTS patients (Jacob et al., 2000).
They demonstrated that norepinephrine spillover, or the nore-
pinephrine that was released at sympathetic synapses and “spilled
over” into the venous circulation, was considerably impaired.
This defect in norepinephrine spillover was predominantly in the
lower extremities. Using a cold pressor test, a nitroprusside infu-
sion, and tyramine infusion, they demonstrated that there was
decreased norepinephrine spillover in POTS patients compared
to healthy subjects in each of the 3 tests (P = 0.02, P = 0.01, and
P = 0.04 respectively). In contrast, systemic and upper extrem-
ity norepinephrine spillovers were unchanged in POTS patients
compared to healthy subjects. Taken together, these data suggest
that some patients in POTS have inadequate sympathetic tone
to the lower extremities leading to diminished vasoconstriction
and venoconstriction. At this point, it is unclear if this is due
to denervation and/or impaired norepinephrine release at the
synaptic cleft of these peripheral sites. Nevertheless, what results
is diminished venous return and decreased stroke volume, with a
secondary increase in central sympathetic nerve traffic that results
in excessive orthostatic tachycardia.
RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM (RAAS) AND
HYPOVOLEMIA IN POTS
Hypovolemia and the “Renin-Aldosterone Paradox”
In more recent years, hormonal research as it relates to the
pathophysiology of POTS has converged on the renin-angiotensin
aldosterone system. Low blood volume (red cell volume and
plasma volume) has been demonstrated in multiple studies in
POTS patients (Jacob et al., 1997; Raj et al., 2005a; Stewart
et al., 2006a; Fu et al., 2010). Raj et al. showed that a cohort
of POTS patients specifically have inappropriately normal levels
of plasma renin activity (PRA) and paradoxically lower levels of
aldosterone (P = 0.017) despite their hypovolemia when com-
pared to healthy subjects (Raj et al., 2005a). PRA activity was
similar even after 30min of standing. In addition, the aldos-
terone: renin ratio was considerably lower in the POTS group
versus the healthy subjects (P = 0.047). Stewart et al. showed that
the “low-flow” group of POTS patients specifically had signif-
icantly lower levels of PRA when compared to healthy subjects
(P < 0.05) (Stewart et al., 2006a). Fu et al. in a study of 10 pre-
menopausal women with POTS, found that PRA significantly
rose after 2 hours of standing compared to healthy subjects,
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while aldosterone did not change significantly (Fu et al., 2010).
They also confirmed a reduced aldosterone:renin ratio in POTS
patients.
Angiotensin II (Ang-II)
Subsequent work has also shown that plasma Ang-II levels in
some POTS patients are elevated when compared to healthy sub-
jects (Stewart et al., 2006a; Mustafa et al., 2011). Ang-II is the
major effector of the RAAS axis, causing systemic vasoconstric-
tion, raising BP, and is critical for maintaining fluid balance
homeostasis through aldosterone secretion (Zhuo and Li, 2011).
Elevations of Ang-II in POTS patients are on the order of 2-3
times higher than healthy subjects (Stewart et al., 2006a; Mustafa
et al., 2011). The absence of hypertension in these patients is
therefore perplexing. Mustafa et al. infused a standard dose of
Ang-II into POTS patients and healthy subjects (Mustafa et al.,
2012). They found that POTS patients have a blunted systemic
vascular and hypertensive response to Ang-II versus healthy sub-
jects. Importantly, Ang-II infusion induced a similar amount of
aldosterone production in POTS patients as it did in healthy sub-
jects. Renal blood flow and vascular response was also unchanged
between POTS patients and healthy subjects (Mustafa et al.,
2012). The full implications of increased plasma Ang-II in POTS
patients is still unclear.
Pleiotropic effects of the AT1 receptor (AT1R)
Ang-II exerts most of its physiologic effects though AT1R (De
Gasparo et al., 2000). This G-protein coupled receptor elicits
multiple cellular responses via coupling to Gq proteins. While
most of its action are rapid and attributed to G-protein med-
itated secondary messengers, there is increasing evidence that
the internalization of Ang-II by AT1R can produce long-lasting
genomic and gene transcriptional effects via continued activa-
tion of intracellular targets (Zhuo and Li, 2011). AT1R is a very
pleiotropic receptor, found in a variety of different tissues, includ-
ing adrenal, neuronal, cardiac, renal, and vascular smooth muscle
cells (De Gasparo et al., 2000). Some of its actions are consistent
throughout the body, while some will vary based on the location
of the receptor. For example, while it generally elicits hyperten-
sive responses via its actions on vascular smooth muscle cells
(VSMC) in most tissue beds, it has hyperproliferative effects only
on VSMC in the cerebral vasculature, and not on VSMC located
peripherally (Hunyady and Catt, 2006). Additionally AT1R also
plays an important role in the central nervous system where Ang-
II acts like a neurotransmitter, modulating BP, salt intake, thirst
mechanisms, and other neuroendocrine processes (De Gasparo
et al., 2000). The pleiotropic nature of this receptor, along with its
multiple pathways of activation, contributes to the versatility of
Ang-II. This concept is relevant to the discussion of POTS phys-
iology because a response will vary based on the specific tissue
being studied.
Microvascular nitric oxide dysfunction
Medow et al. found that there was defective cutaneous vasodi-
lation of the microvasculature mediated by nitric oxide with
local heating in POTS patients versus healthy subjects (Medow
et al., 2005). Neuronal nitrous oxide synthase (nNOS), and not
endothelial nitrous oxide synthase (eNOS), was determined to be
responsible for causing this phenomenon (Stewart et al., 2007).
Ang-II plays an important role in this defect of microvascu-
lar vasodilation because the administration of an angiotensin
type 1 receptor (AT1R) blocker, losartan, reverses this defect
in POTS patients (Stewart et al., 2008). In summary, the skin
blood flow defect present in POTS patients can be simulated
in healthy subjects by infusing a nNOS inhibitor, and can be
reversed in POTS patients by infusing an Ang-II antagonist. These
skin findings may play a role in the dependent acrocyanosis
seen in many POTS patients. There are not yet any studies that
have assessed whether these skin findings have systemic vascular
implications.
Angiotensin converting enzyme 2 (ACE2)
ACE2 is a monocarboxypeptidase that metabolizes Ang-II, an
octapeptide, into Angiotensin 1-7 [Ang(1-7)]. Ang(1-7) has
vasodilatory properties and has actions that generally oppose that
of Ang-II (Chappell, 2007; Zhuo and Li, 2011). Ang(1-7) also
plays a role in skin microvascular dysregulation (Stewart et al.,
2009; Mustafa et al., 2012).
Stewart et al., showed that with local infusion of losartan and
a NOS inhibitor, cutaneous vasodilation due to local heating is
reduced in healthy subjects to the level of POTS patients (Stewart
et al., 2009). However, even in the presence of losartan and a
NOS inhibitor, the infusion of Ang-II can reverse this reduction
in cutaneous vasodilation only in healthy subjects, whereas the
lack of vasodilation persists in POTS patients. The source of this
recovery in vasodilation in healthy subjects after Ang-II infusion
is thought to be peripheral conversion of Ang-II into Ang(1-7) as
addition of an ACE2 inhibitor will sabotage this vasodilation in
healthy subjects. Similarly, in POTS patients, even in the presence
of NOS and losartan, infusion of Ang(1-7) can restore normal
cutaneous vasodilation. Thus, the source of this dysregulation is
thought to represent a deficiency of ACE2 in the skin of POTS
patients.
Mustafa et al. also showed that this deficiency in ACE2 extends
into the systemic circulation by measuring the ratio of Ang(1-7)
to Ang-II and used it as a surrogate for functional ACE2 activity
(Mustafa et al., 2011). In the presence of elevated systemic levels
of Ang-II with comparable levels of Ang1-7, POTS patients had
a significantly lower ratio of Ang(1-7):Ang-II when compared to
healthy subjects (P = 0.038).
Further investigations
The source of ACE2 dysfunction in POTS patients is still unclear.
A specific genetic mutation could be the cause. Alternatively,
ACE2 dysfunction could be a downstream manifestation result-
ing from POTS. As most POTS patients are intolerant of physical
activity, ACE2 dysfunction could be a product of general decon-
ditioning. Prior research has shown that diet, at least in the short
term, does not affect level of ACE2 activity (Mustafa et al., 2011).
Another possibility is that the measured Ang-II might not
really be Ang-II. Most prior studies that have quantified Ang-II
have employed assays that were not sensitive enough to distin-
guish Ang-II from angiotensin 3 or angiotensin 4 since they
typically employed radioimmunoassays that targeted the peptides
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common to the C-terminus (Stewart et al., 2006a; Mustafa et al.,
2011). It is possible that some of themeasured “Ang-II” is actually
angiotensin 3 or angiotensin 4.
The exact mechanism of how a defect in ACE2 might trig-
ger the clinical manifestations of POTS is also still poorly
understood. While there may be a deficiency in peripheral and
cutaneous vasodilation secondary to an ACE2 defect, it is not
clear how that produces orthostatic tachycardia and presyncopal
symptoms.
In addition to the “renin-aldosterone paradox” with the
lack of aldosterone response in the presence of hypovolemia,
the high Ang-II levels and low ACE2 activity remains to be
explained.
HYPERADRENERGIC POTS
Previous studies in normal healthy subjects have demonstrated
normal supine plasma norepinephrine levels to be around
200 pg/mL (Jacob et al., 1998). With standing, upright nore-
pinephrine levels plateau below 600 pg/mL after 7.5min. Supine
plasma epinephrine levels are around 25 pg/mL and increase with
standing up to 70 pg/mL. Numerous studies have documented
comparable supine levels of norepinephrine and epinephrine
between POTS and healthy subjects, but elevated upright nore-
pinephrine (Jacob et al., 2000; Raj et al., 2005a; Mustafa et al.,
2011). Tachycardia is the most salient manifestation of this hyper-
adrenergic state. Another manifestation of increased SNA during
orthostasis in POTS patients includes possibly increasing coher-
ence and blunting cerebral autoregulation leading to decreased
cerebral blood flow (Ocon et al., 2009). However, it should be
noted that there are several studies in the literature with incon-
sistent findings related to cerebral blood flow during orthostasis
in POTS patients (Jordan et al., 1998; Schondorf et al., 2005; Ocon
et al., 2009).
Using muscle sympathetic nerve activity (MSNA) as mea-
sured by microneurography, sympathetic nervous activity (SNA)
in POTS patients has been shown to differ from that of healthy
subjects at rest (Furlan et al., 1998), during orthostasis (Muenter
et al., 2005), or induced hypotension (Bonyhay and Freeman,
2004). Although data available is conflicting regarding resting
SNA activity in POTS patients, POTS patients have an exaggerated
SNA response compared to healthy subjects during orthostatic
and hypotensive challenge (Bonyhay and Freeman, 2004;Muenter
et al., 2005).
One etiology behind this exaggerated SNA response is
attributed to norepinephrine transporter (NET) dysfunction.
Administration of a NET inhibitor, reboxetine, to healthy sub-
jects has been shown to produce a POTS phenotype with increase
of HR in response to head-up tilt testing by greater than 30 bpm
(Schroeder et al., 2002). NET inhibition is thought to increase
norepinephrine concentrations acting on postsynaptic adrenore-
ceptors, which drives the tachycardia in POTS. The dispropor-
tionate response in HR can be explained by the heart’s essential
reliance on the NET (Esler et al., 1991).
This hyperadrenergic state can be “secondary” such as in
response to hypovolemia, or “primary” such as one related to
a genetic mutation. Shannon et al. demonstrated that a specific
genetic mutation can cause POTS. A specific missense mutation
in the exon of the norepinephrine transporter gene (SLC6A2)
produced an Ala457Pro mutation in the norepinephrine trans-
porter causing 98% loss of function (Shannon et al., 2000).
The mutation was isolated in a 33 year old woman with a 20
year history of orthostatic intolerance as well as her identi-
cal twin sister. Plasma supine norepinephrine levels were nor-
mal for both patients (269 pg/mL and 199 pg/mL), but both
patients had upright plasma norepinephrine levels exceeding
900 pg/mL, and 1 patient became hypertensive with standing.
Although most patients with hyperadrenergic POTS do not have
this genome mutation, epigenetic modification at this gene locus
which decreases expression of the NET protein has also been
associated with POTS patients. Bayles et al. demonstrated that
the promoter of the SCL6A2 gene was especially sensitive to
histone modifications that downregulated expression of this pro-
tein (Bayles et al., 2012). The data here demonstrates inhibition of
the norepinephrine clearance transporters, which is a mechanism
ofmany psychotropicmedications, predisposes individuals to ele-
vated levels of upright norepinephrine and can produce a typical
POTS phenotype.
There is also some data that the parasympathetic system may
contribute to the tachycardia in POTS. Furlan et al. reported that
low frequency (0.04–0.15Hz) R-R interval, a marker of parasym-
pathetic activity, was slightly reduced compared to healthy sub-
jects, though this was not statistically significant (Furlan et al.,
1998). Thus, decreased cardiovagal activation due to reduced
parasympathetic nervous system activity and its contribution on
POTS is still unclear.
TREATMENT APPROACHES: ADDRESSING
NEUROHORMONAL IMBALANCES (TABLE 1)
PARTIAL AUTONOMIC NEUROPATHY—ALPHA-1 AGONISTS
Alpha-1 agonists have been used in POTS patients to restore the
lack of adrenergic vasoconstriction due to partial autonomic neu-
ropathy in the lower extremities. Phenylephrine infusions have
previously been shown to improve HR and enhance peripheral
vasoconstriction in POTS patients. However, phenylephrine infu-
sion also increased BP in these patients (Stewart et al., 2002).
Jacob et al. have shown that midodrine, an orally active alpha-
1 agonist at 5-10mg doses, is very effective at reducing the
orthostatic tachycardia at 1 and 2 hours after administration. In
addition it had very minimal effects on the BP and also reduced
supine HR (Jacob et al., 1997). The addition of a beta-blocker in
addition to midodrine enhanced the therapeutic efficacy when
compared to midodrine alone (Lai et al., 2009). More recently,
it was shown that “high-flow” POTS patients were much more
responsive to the treatment of midodrine than “low-flow” POTS
patients (Ross et al., 2014).
Octreotide is a somatostatin analog that causes vasocon-
striction in the splanchnic vascular bed. It has been shown
to significantly reduce orthostatic tachycardia in POTS patients
to a similar extent that midodrine does (Hoeldtke and
Davis, 1991; Hoeldtke et al., 2006). Standing times were
increased when midodrine was added to octreotide treat-
ment in POTS patients, but neither midodrine nor octreotide
alone significantly increased standing times (Hoeldtke et al.,
2006).
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HYPOVOLEMIA AND RENIN-ANGIOTENSIN-ALDOSTERONE
PARADOX—VOLUME LOADING
Fludrocortisone is a potent fluorinated aldosterone agonist that
causes significant sodium and water retention (Thorn et al.,
1955). It has been widely and successfully used for the treatment
neurogenic orthostatic hypotension (Freeman, 2008; Freeman
et al., 2011). Fludrocortisone is also considered a first-line
treatment for POTS and has been shown to improve symp-
toms significantly (Freitas et al., 2000; Raj, 2013). Before start-
ing blood volume expansion agents, medications that directly
antagonize aldosterone, such as spironolactone or drosperinone
(which is found in certain oral contraceptives) should be stopped
first.
Desmopressin (DDAVP) is an orally available synthetic ana-
log of arginine vasopressin. In a study of 30 POTS patients, the
short-term administration of DDAVP orally reduced the degree
of orthostatic tachycardia compared to placebo significantly (P <
0.001). In addition, patients reported significant improvements
in overall symptoms, and specifically symptoms related to vision,
tremulousness, and palpitations (Coffin et al., 2012).
Erythropoietin has also been used to treat the decreased
blood volume in POTS patients by artificially increasing ery-
thropoiesis. Hoeldtke et al. initially found no improvement in
reducing orthostatic tachycardia in a small study involving 8
patients with orthostatic intolerance after 6–12 weeks of ery-
thropoietin treatment. Furthermore, supine as well as standing
BP were elevated (Hoeldtke et al., 1995). In a larger study of
39 POTS patients refractory to conventional treatment, erythro-
poietin administration garnered no improvement in orthostatic
tachycardia. However, a significant proportion (∼80%) of these
patients reported subjective improvement of their symptoms
(Kanjwal et al., 2012).
The use of volume loading with intravenous saline is effective
at acutely relieving the symptoms of POTS. Jacob et al. showed
that the infusion of 1 liter of normal saline over a time period of
1 h was effective in significantly reducing orthostatic tachycardia
at 1 h upon the completion of the infusion (Jacob et al., 1997).
The results of this are short-lived. Some patients have pursued
chronic IV saline infusions, but this is not widely advised due to
concerns about access complications.
Fu et al. conducted a trial before-after exercise training to 3
months of an exercise regimen consisting of 4 sessions per week,
each lasting 30–45min (n = 19) (Fu et al., 2011). The 3 month
exercise program was able to increase the aldosterone:renin ratios
well as the plasma volumes and blood volumes in these POTS
patients. Other benefits included a reduction in orthostatic tachy-
cardia (P < 0.01), and significantly improved quality of life as
assessed by the SF-36.Exercise is the only intervention that has
been shown to improve the aldosterone:renin ratio and increase
plasma and blood volumes over the long term.
HYPERADRENERGIC STATE—HEART RATE CONTROL
Attempts to manage the hyperadrenergic state in these individ-
uals center around HR control. The use of beta-blockade to
decrease HR has been met with conflicting data. Masuki et al.
had previously shown that POTS patients had reduced stroke
volumes and required a faster upright HR to maintain cardiac
output (Masuki et al., 2007). Stewart et al. showed that acute
esmolol infusions did not significantly reduce orthostatic HR
(Stewart et al., 2002). However, Raj et al. showed that the use
of propranolol at a 20mg dose acutely and significantly reduced
orthostatic tachycardia compared to placebo (P = 0.010) up to
4 h after administration (Raj et al., 2009). Low dose propranolol
also improved symptoms significantly during this time. Fu et al.
found that long-acting once daily propranolol did not improve
quality of life at 1 month (Fu et al., 2011).
Pyridostigmine, an acetylcholinesterase inhibitor, has also
been used to manage orthostatic tachycardia (Raj, 2013).
The putative mechanism behind using an acetylcholinesterase
inhibitor is to increase parasympathetic tone by enhancing
cholinergic activity at both the ganglionic nicotinic and the
postganglionic muscarinic acetylcholine receptors (Raj et al.,
2005b). In a study of 17 patients, standing HR was significantly
reduced at 2 and 4 h after pyridostigmine administration vs.
placebo (P < 0.001 for both times). Although pyridostigmine
also acts to enhance sympathetic transduction at nicotinic
ganglia, BP were unaffected. Symptoms also were signifi-
cantly improved 4 h after administration of pyridostigmine.
Subsequent studies by Singer et al. and Kanjwal et al. have
confirmed the long-term benefits of using pyridostigmine
(Singer et al., 2006; Kanjwal et al., 2011).
Given that a defective norepinephrine transporter has been
implicated in causing hyperadrenergic POTS, medications that
inhibit norepinephrine reuptake worsen tachycardia in POTS
patients (Shannon et al., 2000). Vincent et al. showed that
in normal healthy individuals, higher doses of duloxetine,
a serotonin-norepinephrine reuptake inhibitor (SNRI), caused
healthy volunteers to develop a POTS-like phenotype with
increased orthostatic tachycardia (Vincent et al., 2004). Green
et al. have recently reported that atomoxetine increased stand-
ing HR in POTS patients and that it acutely worsened symptom
burden in 2/3 of the POTS patients (Green et al., 2013). In addi-
tion, selective-serotonin reuptake inhibitors (SSRI) have also been
shown to inhibit norepinephrine reuptake, (Shores et al., 2001)
and recent reports show that the acute administration of the
SSRI, sertraline, acutely worsened symptoms in POTS patients
vs. placebo (Mar et al., 2014). These findings must be balanced
against their potential long-term benefits in terms of managing
anxiety from a chronic illness and coping with POTS. Data for
these long-term effects are currently lacking.
CONCLUSIONS
Over the past 20 years, considerable research has taken place in an
effort to understand and explain this enigmatic syndrome. Several
neural and hormonal observations have been made in regard to
the pathophysiology of POTS. POTS patients have variously been
shown to have a partial neuropathic state with impaired lower
extremity sympathetic innervations, abnormal venous pooling,
a hypovolemic state with inadequate RAAS upregulation, cuta-
neous blood flow dysregulation, and also increased plasma Ang-II
levels. In recent years, pathophysiology research for POTS has
shifted toward work on the RAAS, and considerable emphasis has
been placed on the Ang-II/ACE2/Ang(1-7) axis (Stewart et al.,
2008, 2009; Mustafa et al., 2011, 2012).
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As the etiology of POTS is not completely understood, it is
unclear if the Ang-II/ACE2/Ang(1-7) axis is the unifying patho-
logic mechanism that drives the pathophysiology for all the
manifestations of POTS that do not as of yet have a crystal-clear
explanation. Alternatively, the manifestations for each variant
may simply be one of several but typical downstream responses
to a defective Ang-II/ACE2/Ang(1-7) axis or another unifying
pathologic mechanism. If so, then the exact steps that link these
manifestations to that unifying pathologic mechanism will need
to be elucidated.
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